Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-12 · accession 0001193125-25-317983 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-12 | 2025-12-12 | ARTV | Raymon Heather | SVP, Research, Development | A - Grant | $0.00 | +67.3K | 106.8K | +170% | $0 |
| DM | 2025-12-12 | 2025-12-12 | ARTV | Raymon Heather | SVP, Research, Development | D - Sale to Iss | — | -67.3K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | A | A | 67,253 | $0.00 | 106,844 | D | — | — | (F1) Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs"). (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2025-12-12 | D | D | 14,819 | — | 0 | D | $5.01 · — to 2033-04-02 | 14,819 Common Stock | (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F5) 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2025-12-12 | D | D | 12,539 | — | 0 | D | $5.01 · — to 2033-04-02 | 12,539 Common Stock | (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F4) 25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 4 | Derivative | Employee Stock Option (Right to Buy) | 2025-12-12 | D | D | 11,399 | — | 0 | D | $5.18 · — to 2034-01-23 | 11,399 Common Stock | (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F6) Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts. |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2025-12-12 | D | D | 18,239 | — | 0 | D | $5.14 · — to 2030-11-02 | 18,239 Common Stock | (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F3) 25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 6 | Derivative | Employee Stock Option (Right to Buy) | 2025-12-12 | D | D | 10,259 | — | 0 | D | $13.47 · — to 2034-05-01 | 10,259 Common Stock | (F2) On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. (F7) 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |